Interpace Biosciences, Inc. Common Stock
IDXG
IDXG was delisted on the 24th of February, 2021.
12 hedge funds and large institutions have $849K invested in Interpace Biosciences, Inc. Common Stock in 2020 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 7 closing their positions.
33% less funds holding
Funds holding: 18 → 12 (-6)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
60% less capital invested
Capital invested by funds: $2.14M → $849K (-$1.29M)
86% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$38.1K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$6.34K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$880K |
| 2 |
PM
Penbrook Management
New York
|
-$261K |
| 3 |
MFG
Magnus Financial Group
New York
|
-$150K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$37K |
| 5 |
Squarepoint
New York
|
-$14.5K |
IDXG Hedge Fund Activity: Q4 2020 in Review
12 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Interpace Biosciences, Inc. Common Stock (IDXG) for Q4 2020, worth a combined $849K — down 60% from $2.14M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of IDXG and 1 opened new positions — a net loss of 6 holders — while 2 trimmed existing stakes and 1 added.
The largest buyer was Vanguard Group, adding an estimated $38.1K. The largest seller was Stonepine Capital Management, exiting entirely with an estimated $880K sold.
- 12 institutional investors held Interpace Biosciences, Inc. Common Stock (IDXG) as of Q4 2020, down from 18 in Q3 2020.
- Funds reported $849K of Interpace Biosciences, Inc. Common Stock stock for Q4 2020, down 60% quarter-over-quarter.
- 1 fund opened new Interpace Biosciences, Inc. Common Stock positions in Q4 2020 and 7 closed out, a net change of -6 holders.
- The largest Interpace Biosciences, Inc. Common Stock buyer in Q4 2020 was Vanguard Group, an estimated $38.1K added.
- The largest Interpace Biosciences, Inc. Common Stock seller in Q4 2020 was Stonepine Capital Management, an estimated $880K sold.
Based on aggregated 13F filings for Q4 2020.